Wall Street Zen Upgrades Telix Pharmaceuticals (NASDAQ:TLX) to “Hold”

Telix Pharmaceuticals (NASDAQ:TLX) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Friday.

Other analysts have also recently issued reports about the company. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Telix Pharmaceuticals in a research report on Wednesday. Canaccord Genuity Group upgraded Telix Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 6th. Royal Bank Of Canada raised Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research report on Monday. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $21.00.

Telix Pharmaceuticals Trading Down 0.1%

TLX opened at $7.61 on Friday. The company’s 50-day moving average price is $8.44 and its 200 day moving average price is $10.36. Telix Pharmaceuticals has a fifty-two week low of $7.16 and a fifty-two week high of $30.36.

Institutional Trading of Telix Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Rhumbline Advisers grew its stake in shares of Telix Pharmaceuticals by 117.3% in the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after purchasing an additional 1,392 shares in the last quarter. IHT Wealth Management LLC acquired a new stake in Telix Pharmaceuticals in the second quarter worth about $213,000. Blair William & Co. IL acquired a new stake in Telix Pharmaceuticals in the second quarter worth about $217,000. Private Advisor Group LLC grew its position in Telix Pharmaceuticals by 67.3% in the 3rd quarter. Private Advisor Group LLC now owns 42,112 shares of the company’s stock valued at $403,000 after buying an additional 16,945 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in Telix Pharmaceuticals during the 2nd quarter valued at about $297,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.